

Novartis India Limited

Regd. off: Sandoz House, Shivsagar Estate, Dr Annie Besant Road, Worli, Mumbai 400 018

in ` million					
PART I					
STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED 30TH JUNE 2013					
	Particulars	3 months ended	3 months ended	3 months ended	Year ended
		30.6.2013	31.3.2013	30.6.2012	31.3.2013
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1.	Income from Operations				
	(a) Net Sales/Income from Operations (Net of Excise Duty)	2,190.3	2,082.1	2,153.0	8,861.0
	(b) Other Operating Income	40.7	46.4	42.4	172.6
	Total Income from Operations (Net)	2,231.0	2,128.5	2,195.4	9,033.6
2.	Expenses				
	(a) Cost of Materials Consumed	121.1	127.2	68.9	403.6
	(b) Purchases of Stock-in-Trade	802.4	913.1	817.4	3,579.3
	(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	81.8	(163.8)	(26.2)	(266.4)
	(d) Employee Benefits Expense	459.0	424.1	411.1	1,623.0
	(e) Depreciation and Amortisation Expense	9.3	10.1	7.6	35.9
	(f) Other Expenses	740.0	742.7	731.6	2,793.7
	Total Expenses	2,213.6	2,053.4	2,010.4	8,169.1
3.	Profit from Operations before Other Income and Finance Costs	17.4	75.1	185.0	864.5
4.	Other Income	205.5	223.0	212.0	831.9
5.	Profit from Ordinary Activities before Finance Costs	222.9	298.1	397.0	1,696.4
6.	Finance Costs	0.7	0.5	0.8	2.2
7.	Profit from Ordinary Activities before Tax	222.2	297.6	396.2	1,694.2
8.	Tax Expense (including Deferred Tax)	83.5	53.5	126.4	496.9
9.	Net Profit for the period	138.7	244.1	269.8	1,197.3
10.	Paid-up Equity Share Capital (Face Value ` 5 each)	159.8	159.8	159.8	159.8
11.	Reserves excluding Revaluation Reserves (as per last audited Balance Sheet)				8,842.3
12.	Earnings Per Share - (of ` 5 each) (not annualised) Basic and Diluted (`)	4.34	7.64	8.44	37.46

PART II					
SELECT INFORMATION FOR THE QUARTER ENDED 30TH JUNE 2013					
	Particulars	3 months ended	3 months ended	3 months ended	Year ended
		30.6.2013	31.3.2013	30.6.2012	31.3.2013
A	PARTICULARS OF SHAREHOLDING				
1.	Public Shareholding				
	- Number of Shares	7,990,200	7,535,995	7,535,995	7,535,995
	- Percentage of Shareholding	25.00	23.58	23.58	23.58
2.	Promoter and Promoter Group Shareholding				
	(a) Pledged / Encumbered				
	- Number of Shares	-	-	-	-
	- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	-	-	-	-
	- Percentage of Shares (as a % of the total Share Capital of the company)	-	-	-	-
	(b) Non-Encumbered				
	- Number of Shares	23,970,597	24,424,802	24,424,802	24,424,802
	- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	100.0	100.0	100.0	100.00
	- Percentage of Shares (as a % of the total Share Capital of the company)	75.00	76.42	76.42	76.42

Particulars	3 months ended
	30.6.2013
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	-
Received during the quarter	-
Disposed of during the quarter	-
Remaining unsolved at the end of the quarter	-

SEGMENT REVENUE, RESULTS AND CAPITAL EMPLOYED

in ` million

Sr. No	Particulars	3 months ended	3 months ended	3 months ended	Year ended
		30.6.2013 (Unaudited)	31.3.2013 (Unaudited)	30.6.2012 (Unaudited)	31.3.2013 (Audited)
1.	Segment Revenue				
	(a) Pharmaceuticals	1,627.8	1,425.0	1,619.9	6,348.5
	(b) Generics	149.2	162.4	157.3	625.2
	(c) OTC	198.5	299.2	198.7	1,104.6
	(d) Animal Health	255.5	241.9	219.5	955.3
	Total Income from Operations (Net)	2,231.0	2,128.5	2,195.4	9,033.6
2.	Segment Results				
	(a) Pharmaceuticals	110.3	51.6	206.5	737.8
	(b) Generics	18.8	45.7	56.9	220.8
	(c) OTC	(23.2)	55.5	(2.0)	162.5
	(d) Animal Health	(1.5)	13.6	6.8	40.2
	Total	104.4	166.4	268.2	1,161.3
	Add/(Less):				
	(a) Finance Costs	(0.7)	3.6	(0.8)	(2.2)
	(b) Other Unallocable Expenditure	(77.4)	(89.4)	(82.9)	(290.9)
	(c) Other Unallocable Income	195.9	217.0	211.7	826.0
	Profit from Ordinary Activities before Tax	222.2	297.6	396.2	1,694.2
3.	Capital Employed (Segment Assets less Segment Liabilities)				
	(a) Pharmaceuticals	206.0	258.7	280.5	258.7
	(b) Generics	157.2	103.5	81.6	103.5
	(c) OTC	1.0	(53.8)	53.1	(53.8)
	(d) Animal Health	339.7	326.5	302.6	326.5
	Total	703.9	634.9	717.8	634.9
	Add: Unallocable Corporate Assets less Unallocable Corporate Liabilities	8,436.9	8,367.2	7,730.7	8,367.2
	Total Capital Employed	9,140.8	9,002.1	8,448.5	9,002.1

Notes:

- On 30th May 2013, Novartis AG reduced its promoter shareholding in the company to 75% enabling the company to comply with the minimum 25% public shareholding requirements as set out in Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended.
- The figures for the quarter ended 31st March 2013 are the balancing figures between the audited financial results for the year ended 31st March 2013 and the published unaudited financial results for the nine months ended 31st December 2012.
- The above results were reviewed by the Audit Committee at its meeting held on 24th July 2013 and approved at the meeting of the Board of Directors held on that date.
- The results for the quarter ended 30th June 2013 have been subjected to limited review by the statutory auditors of the company.
- Figures for the prior periods have been regrouped where necessary.

By Order of the Board

Ranjit Shahani
Vice Chairman and Managing Director
Mumbai, 24th July 2013